Bertrand Allard

List of Publications by Citations

28 papers	2,204 citations	18 h-index	30 g-index
30 ext. papers	2,768 ext. citations	7.3 avg, IF	5.49 L-index

#	Paper	IF	Citations
28	The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets. *Immunological Reviews*, **2017**, 276, 121-144	11.3	414
27	Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. *Clinical Cancer Research*, **2013**, 19, 5626-35	12.9	293
26	Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses. *Cancer Immunology Research*, **2015**, 3, 506-17	12.5	198
25	Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor. *Cancer Research*, **2014**, 74, 3652-8	10.1	178
24	Immunosuppressive activities of adenosine in cancer. *Current Opinion in Pharmacology*, **2016**, 29, 7-16	5.1	156
23	CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer. *Clinical Cancer Research*, **2016**, 22, 158-66	12.9	121
22	Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects. *Therapeutic Advances in Medical Oncology*, **2013**, 5, 169-81	5.4	121
21	Anti-CD73 therapy impairs tumor angiogenesis. *International Journal of Cancer*, **2014**, 134, 1466-73	7.5	108
20	The adenosine pathway in immuno-oncology. *Nature Reviews Clinical Oncology*, **2020**, 17, 611-629	19.4	101
19	CD73-adenosine: a next-generation target in immuno-oncology. *Immunotherapy*, **2016**, 8, 145-63	3.8	82
18	Targeting the CD73-adenosine axis in immuno-oncology. *Immunology Letters*, **2019**, 205, 31-39	4.1	73
17	CD73-generated adenosine: orchestrating the tumor-stroma interplay to promote cancer growth. *Journal of Biomedicine and Biotechnology*, **2012**, 2012, 485156		64
16	A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment. *Neoplasia*, **2017**, 19, 530-536	6.4	46
15	On the mechanism of anti-CD39 immune checkpoint therapy **2020**, 8,		42
14	Targeting the adenosine pathway for cancer immunotherapy. *Seminars in Immunology*, **2019**, 42, 101304	10.7	37
13	Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer. *Expert Opinion on Therapeutic Targets*, **2014**, 18, 863-81	6.4	30
12	CD73 plays a protective role in collagen-induced arthritis. *Journal of Immunology*, **2015**, 194, 2487-92	5.3	27

List of Publications

11	CD73-adenosine reduces immune responses and survival in ovarian cancer patients. *OncoImmunology*, **2016**, 5, e1127496	7.2	27
10	Co-blockade of immune checkpoints and adenosine A receptor suppresses metastasis. *OncoImmunology*, **2014**, 3, e958952	7.2	18
9	Generation and characterization of rendomab-B1, a monoclonal antibody displaying potent and specific antagonism of the human endothelin B receptor. *MAbs*, **2013**, 5, 56-69	6.6	17
8	Electroporation-aided DNA immunization generates polyclonal antibodies against the native conformation of human endothelin B receptor. *DNA and Cell Biology*, **2011**, 30, 727-37	3.6	11
7	Adenosine A2a receptor promotes lymphangiogenesis and lymph node metastasis. *OncoImmunology*, **2019**, 8, 1601481	7.2	10
6	WISP1 is associated to advanced disease, EMT and an inflamed tumor microenvironment in multiple solid tumors. *OncoImmunology*, **2019**, 8, e1581545	7.2	9
5	Rendomab B4, a monoclonal antibody that discriminates the human endothelin B receptor of melanoma cells and inhibits their migration. *MAbs*, **2016**, 8, 1371-1385	6.6	6
4	Methods to Evaluate the Antitumor Activity of Immune Checkpoint Inhibitors in Preclinical Studies. *Methods in Molecular Biology*, **2016**, 1458, 159-77	1.4	5
3	Kinetic Study of Human Full-Length Wild-Type JAK2 and V617F Mutant Proteins. *The Open Enzyme Inhibition Journal*, **2009**, 1, 80-84	0	5
2	Measurement of CD73 enzymatic activity using luminescence-based and colorimetric assays. *Methods in Enzymology*, **2019**, 629, 269-289	1.7	3
1	Abstract 3361: CD73 expression on tumor-infiltrating breast cancer leukocytes **2015**,		2